Peripheral blood

PROCEDURE11 trials

Sponsors

Washington University School of Medicine, Mitchell Grayson, National Taiwan University Hospital, Memorial Sloan Kettering Cancer Center, Leids Universitair Medisch Centrum

Conditions

CancerCancer of Head and NeckCarcinoma, Squamous Cell of Head and NeckCovid-19Epithelial Ovarian CancerFallopian Tube CancerHead and Neck CancerHead and Neck Squamous Cell Carcinoma

Phase 1

BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

CompletedNCT03496662

Washington University School of MedicinePancreatic Ductal Adenocarcinoma

Start: 2018-08-31End: 2024-07-25Updated: 2025-07-29

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

CompletedNCT03532217

Washington University School of MedicineMetastatic Hormone-Sensitive Prostate Cancer

Start: 2018-09-14End: 2022-07-25Updated: 2022-08-05

Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy

WithdrawnNCT03607955

Washington University School of MedicineEpithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer

Start: 2021-06-30End: 2029-08-31Updated: 2021-09-29

Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy

TerminatedNCT03655444

Washington University School of MedicineHead and Neck Squamous Cell Carcinoma

Start: 2019-05-29End: 2020-08-24Updated: 2020-12-03

Phase 2

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

CompletedNCT02296684

Washington University School of MedicineCancer of Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck +3

Start: 2015-03-25End: 2025-07-21Updated: 2026-08-05

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

CompletedNCT03623373

Washington University School of MedicineMantle Cell Lymphoma

Start: 2018-11-29End: 2025-04-14Updated: 2026-04-21

A Study of N-acetylcysteine in Patients With COVID-19 Infection

Active, not recruitingNCT04374461

Memorial Sloan Kettering Cancer CenterCovid-19

Start: 2020-05-01End: 2027-05-01Updated: 2026-05-01

Unknown Phase

Leukotriene Antagonism in Recruitment of CD49d Expressing Neutrophils in Atopic Subjects

CompletedNCT03039101

Mitchell GraysonNasal Allergy

Start: 2017-09-06End: 2018-07-16Updated: 2019-10-07

Mass cytometry-based analysis of the composition of the immune system in peripheral blood and cerebrospinal fluid in narcolepsy

Active, not recruitingNL-OMON45374

Leids Universitair Medisch Centrumnarcolepsy sleep disorders

Start: 2017-12-19Target: 20Updated: 2024-02-28

Production of Clinical-grade Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory B-cell Malignancies

National Taiwan University HospitalLeukemia

Start: 2018-03-09End: 2020-12-31Target: 130Updated: 2018-08-10

Palliative Lattice Stereotactic Body Radiotherapy (SBRT)

CompletedNCT04133415

Washington University School of MedicineCancer, Palliative Radiotherapy

Start: 2019-10-31End: 2020-12-14Updated: 2021-11-22

Related Papers

Data from Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer

2025-09-02

5-year survival outcomes after perioperative pembrolizumab (pembro) in patients with human papillomavirus (HPV)-unrelated, locally advanced head and neck squamous cell carcinoma (LA-HNSCC): A multi-center, two-cohort, phase 2 trial.

Journal of Clinical Oncology2025-05-28

Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial

Nature Communications2025-05-178 citations

Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer

Clinical Cancer Research2025-03-214 citations

Abstract PO-002: Pembrolizumab as neoadjuvant and adjuvant therapy in combination with standard of care in resectable, locally advanced head and neck squamous cell carcinoma: Phase 3 KEYNOTE-689

Clinical Cancer Research2023-09-154 citations

Abstract PO-078: Tissue-resident memory CD8+ T cells correlate with anti-PD-1 response in head and neck cancer and expand upon cDC1 activation in tumor-draining lymph nodes to overcome PD-1 resistance

Clinical Cancer Research2023-09-15

Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancer

Science Immunology2023-09-08100 citations

503 Cytotoxic revival is implicated in response to neoadjuvant PD-1 blockade for head and neck squamous cell carcinoma

Regular and Young Investigator Award Abstracts2022-11-012 citations

529 Reduced dendritic cell infiltration in anti-PD-1 resistant head and neck squamous cell carcinoma

Regular and Young Investigator Award Abstracts2022-11-01

A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology2022-06-018 citations

LITE SABR M1: Planning design and dosimetric endpoints for a phase I trial of lattice SBRT.

2021-12-0915 citations

A pilot study on intravenous N-Acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome.

2021-06-1037 citations

Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC).

Journal of Clinical Oncology2021-05-2038 citations

A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology2021-02-205 citations

Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells

Nature Communications2021-02-16149 citations

Spatially fractionated stereotactic body radiation therapy (Lattice) for large tumors

Advances in Radiation Oncology2021-01-1084 citations

A Pilot Study of Acalabrutinib with Bendamustine/Rituximab Followed By Cytarabine/Rituximab (R-ABC) for Untreated Mantle Cell Lymphoma

Blood2020-11-042 citations

Protective Role of Glutathione against Peroxynitrite-Mediated DNA Damage During Acute Inflammation

Chemical Research in Toxicology2020-09-0718 citations

Abstract CT285: KEYNOTE-689: A phase 3 study of neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)

Cancer Research2020-08-159 citations

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

Clinical Cancer Research2020-07-14338 citations

3 more papers not shown